44 active shortage notices across 10 countries.
Last updated 2 Aug 2026 · sourced from official medicines regulators
| European Union | high | 1 | 4 Dec 2024 | — | EMA |
| Netherlands | medium | 18 | 17 Mar 2026 | — | CBG-MEB |
| Germany | medium | 9 | 1 Aug 2024 | 30 Dec 2026 | BfArM |
| Ireland | medium | 3 | 1 Sept 2024 | 1 Feb 2027 | HPRA |
| Croatia | medium | 2 | 22 May 2026 | — | HALMED |
| Portugal | medium | 2 | 9 Jun 2026 | — | INFARMED |
| United States | medium | 1 | 8 Apr 2026 | — | FDA |
| Spain | medium | 1 | 10 Jul 2024 | 29 Oct 2026 | AEMPS |
Yes. As of the latest regulator updates, Aprepitant has 44 active shortage notices across 10 countries (Australia, Italy, European Union, Netherlands, Germany, Ireland and more). Status is refreshed daily from official regulatory sources.
Regulators attribute the current Aprepitant shortages to manufacturing problems, supply-chain disruption, distribution issues. The exact cause varies by country and product — each notice on this page links to the official source.
Regulator-estimated resolution dates currently range from 24 Apr 2026 to 25 Sept 2027, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.